Healthcare

Bio-Rad sells life science and clinical diagnostics tools used in labs and hospitals worldwide. Its niche positions in droplet digital PCR, quality controls, and recurring consumables stand out, while improving cash flow and earnings recovery make its operating picture worth a closer look.

Nurix Therapeutics is building cancer and immune-disease drugs through targeted protein degradation, backed by partnerships and an advancing pipeline. The appeal rests on platform credibility and clinical progress, with future potential carrying far more weight than current earnings.

Neogen supplies food and animal safety products used in testing, sanitation, diagnostics, and biosecurity. The company operates in resilient end markets, and recent cash flow improvement plus integration progress make its longer-term earnings recovery worth a closer look.

Telix Pharmaceuticals has grown into a commercial radiopharmaceutical company with strong momentum in prostate cancer imaging. Its appeal comes from rapid revenue expansion, a foothold in precision oncology, and the possibility of building a broader cancer platform from that base.